Postoperative pain
Conditions
Interventions
group A:Group A intravenous injection of esketamine 0.2 mg/kg
Group B:Group B intravenous injection of esketamine 0.3 mg/kg
Group C:Group C intravenous injection of esketamine 0.4 mg/kg
Sponsors
Department of Anesthesiology, Xiangya Second Hospital, Central South University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients with general anesthesia intubation orthopedic surgery; 2. Aged > 60 years old; 3. ASA grade I ~ III; 4. BMI 18 ~ 30 (including boundary value); 5. Fully understand this study and voluntarily sign informed consent
Exclusion criteria
Exclusion criteria: 1. Intolerance or allergy to ketamine, propofol and sufentanil combined with ketamine contraindications such as glaucoma; 2. Patients with preoperative disturbance of consciousness or mental state or history of central nervous system, history of drug abuse and alcoholism; 3. Dysaudia and language expression disorder, unable to communicate; 4. Patients with other significant pain other than the expected operation pain, or patients with neurological disease, mental disease or mental retardation who can not correctly describe their own feelings or understand the pain scale score, or have other obstacles that interfere with pain assessment; 5. Patients with viral hepatitis, severe active liver disease, abnormal liver function (ALT and / or ast >1.5 ULN) 5 ULN or total bilirubin >=1.5 ULN, abnormal renal function, serum creatinine > 1.5 ULN or creatinine clearance rate =grade II), or significantly abnormal ECG at the time of screening and baseline determined by the researcher; or other abnormal cardiac function judged by the researcher with clinical significance; 8. Relevant researchers of this study; 9. Participated in other clinical trials within 4 weeks before operation; 10. According to the judgment of the researchers, they can not understand the research process and the use of pain scale, and can not communicate effectively with researchers; 11. There are other situations that the researchers judge are not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score;cam score;s-100; | — |
Countries
China
Contacts
Public ContactWang Yaping
Outcome results
None listed